Global Immunotherapy Drugs for Neuroblastoma Supply, Demand and Key Producers, 2023-2029
The global Immunotherapy Drugs for Neuroblastoma market size is expected to reach $ 63 million by 2029, rising at a market growth of 4.4% CAGR during the forecast period (2023-2029).
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
This report studies the global Immunotherapy Drugs for Neuroblastoma production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Immunotherapy Drugs for Neuroblastoma, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Immunotherapy Drugs for Neuroblastoma that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Immunotherapy Drugs for Neuroblastoma total production and demand, 2018-2029, (K Units)
Global Immunotherapy Drugs for Neuroblastoma total production value, 2018-2029, (USD Million)
Global Immunotherapy Drugs for Neuroblastoma production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Immunotherapy Drugs for Neuroblastoma consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Immunotherapy Drugs for Neuroblastoma domestic production, consumption, key domestic manufacturers and share
Global Immunotherapy Drugs for Neuroblastoma production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Immunotherapy Drugs for Neuroblastoma production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Immunotherapy Drugs for Neuroblastoma production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Immunotherapy Drugs for Neuroblastoma market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Immunotherapy Drugs for Neuroblastoma market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Immunotherapy Drugs for Neuroblastoma Market, By Region:
1. How big is the global Immunotherapy Drugs for Neuroblastoma market?
2. What is the demand of the global Immunotherapy Drugs for Neuroblastoma market?
3. What is the year over year growth of the global Immunotherapy Drugs for Neuroblastoma market?
4. What is the production and production value of the global Immunotherapy Drugs for Neuroblastoma market?
5. Who are the key producers in the global Immunotherapy Drugs for Neuroblastoma market?
6. What are the growth factors driving the market demand?
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
This report studies the global Immunotherapy Drugs for Neuroblastoma production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Immunotherapy Drugs for Neuroblastoma, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Immunotherapy Drugs for Neuroblastoma that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Immunotherapy Drugs for Neuroblastoma total production and demand, 2018-2029, (K Units)
Global Immunotherapy Drugs for Neuroblastoma total production value, 2018-2029, (USD Million)
Global Immunotherapy Drugs for Neuroblastoma production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Immunotherapy Drugs for Neuroblastoma consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Immunotherapy Drugs for Neuroblastoma domestic production, consumption, key domestic manufacturers and share
Global Immunotherapy Drugs for Neuroblastoma production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Immunotherapy Drugs for Neuroblastoma production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Immunotherapy Drugs for Neuroblastoma production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Immunotherapy Drugs for Neuroblastoma market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Immunotherapy Drugs for Neuroblastoma market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Immunotherapy Drugs for Neuroblastoma Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Dinutuximab
- Naxitamab
- Other
- Hospital
- Clinic
- Other
- United Therapeutics
- Y-mAbs Therapeutics
- EUSA Pharma
- ANI Pharmaceuticals
- Baxter Healthcare
- Ingenus Pharmaceuticals
- Pfizer
- Hikma Pharmaceuticals
- Teva Pharmaceuticals
1. How big is the global Immunotherapy Drugs for Neuroblastoma market?
2. What is the demand of the global Immunotherapy Drugs for Neuroblastoma market?
3. What is the year over year growth of the global Immunotherapy Drugs for Neuroblastoma market?
4. What is the production and production value of the global Immunotherapy Drugs for Neuroblastoma market?
5. Who are the key producers in the global Immunotherapy Drugs for Neuroblastoma market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Immunotherapy Drugs for Neuroblastoma Introduction
1.2 World Immunotherapy Drugs for Neuroblastoma Supply & Forecast
1.2.1 World Immunotherapy Drugs for Neuroblastoma Production Value (2018 & 2022 & 2029)
1.2.2 World Immunotherapy Drugs for Neuroblastoma Production (2018-2029)
1.2.3 World Immunotherapy Drugs for Neuroblastoma Pricing Trends (2018-2029)
1.3 World Immunotherapy Drugs for Neuroblastoma Production by Region (Based on Production Site)
1.3.1 World Immunotherapy Drugs for Neuroblastoma Production Value by Region (2018-2029)
1.3.2 World Immunotherapy Drugs for Neuroblastoma Production by Region (2018-2029)
1.3.3 World Immunotherapy Drugs for Neuroblastoma Average Price by Region (2018-2029)
1.3.4 North America Immunotherapy Drugs for Neuroblastoma Production (2018-2029)
1.3.5 Europe Immunotherapy Drugs for Neuroblastoma Production (2018-2029)
1.3.6 China Immunotherapy Drugs for Neuroblastoma Production (2018-2029)
1.3.7 Japan Immunotherapy Drugs for Neuroblastoma Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Immunotherapy Drugs for Neuroblastoma Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Immunotherapy Drugs for Neuroblastoma Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Immunotherapy Drugs for Neuroblastoma Demand (2018-2029)
2.2 World Immunotherapy Drugs for Neuroblastoma Consumption by Region
2.2.1 World Immunotherapy Drugs for Neuroblastoma Consumption by Region (2018-2023)
2.2.2 World Immunotherapy Drugs for Neuroblastoma Consumption Forecast by Region (2024-2029)
2.3 United States Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.4 China Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.5 Europe Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.6 Japan Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.7 South Korea Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.8 ASEAN Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.9 India Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
3 WORLD IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Immunotherapy Drugs for Neuroblastoma Production Value by Manufacturer (2018-2023)
3.2 World Immunotherapy Drugs for Neuroblastoma Production by Manufacturer (2018-2023)
3.3 World Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023)
3.4 Immunotherapy Drugs for Neuroblastoma Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Immunotherapy Drugs for Neuroblastoma Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Immunotherapy Drugs for Neuroblastoma in 2022
3.5.3 Global Concentration Ratios (CR8) for Immunotherapy Drugs for Neuroblastoma in 2022
3.6 Immunotherapy Drugs for Neuroblastoma Market: Overall Company Footprint Analysis
3.6.1 Immunotherapy Drugs for Neuroblastoma Market: Region Footprint
3.6.2 Immunotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
3.6.3 Immunotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Immunotherapy Drugs for Neuroblastoma Production Value Comparison
4.1.1 United States VS China: Immunotherapy Drugs for Neuroblastoma Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Immunotherapy Drugs for Neuroblastoma Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Immunotherapy Drugs for Neuroblastoma Production Comparison
4.2.1 United States VS China: Immunotherapy Drugs for Neuroblastoma Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Immunotherapy Drugs for Neuroblastoma Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Immunotherapy Drugs for Neuroblastoma Consumption Comparison
4.3.1 United States VS China: Immunotherapy Drugs for Neuroblastoma Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Immunotherapy Drugs for Neuroblastoma Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Immunotherapy Drugs for Neuroblastoma Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Immunotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value (2018-2023)
4.4.3 United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production (2018-2023)
4.5 China Based Immunotherapy Drugs for Neuroblastoma Manufacturers and Market Share
4.5.1 China Based Immunotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value (2018-2023)
4.5.3 China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production (2018-2023)
4.6 Rest of World Based Immunotherapy Drugs for Neuroblastoma Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Immunotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Immunotherapy Drugs for Neuroblastoma Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Dinutuximab
5.2.2 Naxitamab
5.2.3 Other
5.3 Market Segment by Type
5.3.1 World Immunotherapy Drugs for Neuroblastoma Production by Type (2018-2029)
5.3.2 World Immunotherapy Drugs for Neuroblastoma Production Value by Type (2018-2029)
5.3.3 World Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Immunotherapy Drugs for Neuroblastoma Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Immunotherapy Drugs for Neuroblastoma Production by Application (2018-2029)
6.3.2 World Immunotherapy Drugs for Neuroblastoma Production Value by Application (2018-2029)
6.3.3 World Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 United Therapeutics
7.1.1 United Therapeutics Details
7.1.2 United Therapeutics Major Business
7.1.3 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
7.1.4 United Therapeutics Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 United Therapeutics Recent Developments/Updates
7.1.6 United Therapeutics Competitive Strengths & Weaknesses
7.2 Y-mAbs Therapeutics
7.2.1 Y-mAbs Therapeutics Details
7.2.2 Y-mAbs Therapeutics Major Business
7.2.3 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
7.2.4 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Y-mAbs Therapeutics Recent Developments/Updates
7.2.6 Y-mAbs Therapeutics Competitive Strengths & Weaknesses
7.3 EUSA Pharma
7.3.1 EUSA Pharma Details
7.3.2 EUSA Pharma Major Business
7.3.3 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product and Services
7.3.4 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 EUSA Pharma Recent Developments/Updates
7.3.6 EUSA Pharma Competitive Strengths & Weaknesses
7.4 ANI Pharmaceuticals
7.4.1 ANI Pharmaceuticals Details
7.4.2 ANI Pharmaceuticals Major Business
7.4.3 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
7.4.4 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 ANI Pharmaceuticals Recent Developments/Updates
7.4.6 ANI Pharmaceuticals Competitive Strengths & Weaknesses
7.5 Baxter Healthcare
7.5.1 Baxter Healthcare Details
7.5.2 Baxter Healthcare Major Business
7.5.3 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product and Services
7.5.4 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Baxter Healthcare Recent Developments/Updates
7.5.6 Baxter Healthcare Competitive Strengths & Weaknesses
7.6 Ingenus Pharmaceuticals
7.6.1 Ingenus Pharmaceuticals Details
7.6.2 Ingenus Pharmaceuticals Major Business
7.6.3 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
7.6.4 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
7.6.6 Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
7.7 Pfizer
7.7.1 Pfizer Details
7.7.2 Pfizer Major Business
7.7.3 Pfizer Immunotherapy Drugs for Neuroblastoma Product and Services
7.7.4 Pfizer Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Pfizer Recent Developments/Updates
7.7.6 Pfizer Competitive Strengths & Weaknesses
7.8 Hikma Pharmaceuticals
7.8.1 Hikma Pharmaceuticals Details
7.8.2 Hikma Pharmaceuticals Major Business
7.8.3 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
7.8.4 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Hikma Pharmaceuticals Recent Developments/Updates
7.8.6 Hikma Pharmaceuticals Competitive Strengths & Weaknesses
7.9 Teva Pharmaceuticals
7.9.1 Teva Pharmaceuticals Details
7.9.2 Teva Pharmaceuticals Major Business
7.9.3 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
7.9.4 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Teva Pharmaceuticals Recent Developments/Updates
7.9.6 Teva Pharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Immunotherapy Drugs for Neuroblastoma Industry Chain
8.2 Immunotherapy Drugs for Neuroblastoma Upstream Analysis
8.2.1 Immunotherapy Drugs for Neuroblastoma Core Raw Materials
8.2.2 Main Manufacturers of Immunotherapy Drugs for Neuroblastoma Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Immunotherapy Drugs for Neuroblastoma Production Mode
8.6 Immunotherapy Drugs for Neuroblastoma Procurement Model
8.7 Immunotherapy Drugs for Neuroblastoma Industry Sales Model and Sales Channels
8.7.1 Immunotherapy Drugs for Neuroblastoma Sales Model
8.7.2 Immunotherapy Drugs for Neuroblastoma Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Immunotherapy Drugs for Neuroblastoma Introduction
1.2 World Immunotherapy Drugs for Neuroblastoma Supply & Forecast
1.2.1 World Immunotherapy Drugs for Neuroblastoma Production Value (2018 & 2022 & 2029)
1.2.2 World Immunotherapy Drugs for Neuroblastoma Production (2018-2029)
1.2.3 World Immunotherapy Drugs for Neuroblastoma Pricing Trends (2018-2029)
1.3 World Immunotherapy Drugs for Neuroblastoma Production by Region (Based on Production Site)
1.3.1 World Immunotherapy Drugs for Neuroblastoma Production Value by Region (2018-2029)
1.3.2 World Immunotherapy Drugs for Neuroblastoma Production by Region (2018-2029)
1.3.3 World Immunotherapy Drugs for Neuroblastoma Average Price by Region (2018-2029)
1.3.4 North America Immunotherapy Drugs for Neuroblastoma Production (2018-2029)
1.3.5 Europe Immunotherapy Drugs for Neuroblastoma Production (2018-2029)
1.3.6 China Immunotherapy Drugs for Neuroblastoma Production (2018-2029)
1.3.7 Japan Immunotherapy Drugs for Neuroblastoma Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Immunotherapy Drugs for Neuroblastoma Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Immunotherapy Drugs for Neuroblastoma Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Immunotherapy Drugs for Neuroblastoma Demand (2018-2029)
2.2 World Immunotherapy Drugs for Neuroblastoma Consumption by Region
2.2.1 World Immunotherapy Drugs for Neuroblastoma Consumption by Region (2018-2023)
2.2.2 World Immunotherapy Drugs for Neuroblastoma Consumption Forecast by Region (2024-2029)
2.3 United States Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.4 China Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.5 Europe Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.6 Japan Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.7 South Korea Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.8 ASEAN Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.9 India Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029)
3 WORLD IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Immunotherapy Drugs for Neuroblastoma Production Value by Manufacturer (2018-2023)
3.2 World Immunotherapy Drugs for Neuroblastoma Production by Manufacturer (2018-2023)
3.3 World Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023)
3.4 Immunotherapy Drugs for Neuroblastoma Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Immunotherapy Drugs for Neuroblastoma Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Immunotherapy Drugs for Neuroblastoma in 2022
3.5.3 Global Concentration Ratios (CR8) for Immunotherapy Drugs for Neuroblastoma in 2022
3.6 Immunotherapy Drugs for Neuroblastoma Market: Overall Company Footprint Analysis
3.6.1 Immunotherapy Drugs for Neuroblastoma Market: Region Footprint
3.6.2 Immunotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
3.6.3 Immunotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Immunotherapy Drugs for Neuroblastoma Production Value Comparison
4.1.1 United States VS China: Immunotherapy Drugs for Neuroblastoma Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Immunotherapy Drugs for Neuroblastoma Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Immunotherapy Drugs for Neuroblastoma Production Comparison
4.2.1 United States VS China: Immunotherapy Drugs for Neuroblastoma Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Immunotherapy Drugs for Neuroblastoma Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Immunotherapy Drugs for Neuroblastoma Consumption Comparison
4.3.1 United States VS China: Immunotherapy Drugs for Neuroblastoma Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Immunotherapy Drugs for Neuroblastoma Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Immunotherapy Drugs for Neuroblastoma Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Immunotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value (2018-2023)
4.4.3 United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production (2018-2023)
4.5 China Based Immunotherapy Drugs for Neuroblastoma Manufacturers and Market Share
4.5.1 China Based Immunotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value (2018-2023)
4.5.3 China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production (2018-2023)
4.6 Rest of World Based Immunotherapy Drugs for Neuroblastoma Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Immunotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Immunotherapy Drugs for Neuroblastoma Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Dinutuximab
5.2.2 Naxitamab
5.2.3 Other
5.3 Market Segment by Type
5.3.1 World Immunotherapy Drugs for Neuroblastoma Production by Type (2018-2029)
5.3.2 World Immunotherapy Drugs for Neuroblastoma Production Value by Type (2018-2029)
5.3.3 World Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Immunotherapy Drugs for Neuroblastoma Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Immunotherapy Drugs for Neuroblastoma Production by Application (2018-2029)
6.3.2 World Immunotherapy Drugs for Neuroblastoma Production Value by Application (2018-2029)
6.3.3 World Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 United Therapeutics
7.1.1 United Therapeutics Details
7.1.2 United Therapeutics Major Business
7.1.3 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
7.1.4 United Therapeutics Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 United Therapeutics Recent Developments/Updates
7.1.6 United Therapeutics Competitive Strengths & Weaknesses
7.2 Y-mAbs Therapeutics
7.2.1 Y-mAbs Therapeutics Details
7.2.2 Y-mAbs Therapeutics Major Business
7.2.3 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
7.2.4 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Y-mAbs Therapeutics Recent Developments/Updates
7.2.6 Y-mAbs Therapeutics Competitive Strengths & Weaknesses
7.3 EUSA Pharma
7.3.1 EUSA Pharma Details
7.3.2 EUSA Pharma Major Business
7.3.3 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product and Services
7.3.4 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 EUSA Pharma Recent Developments/Updates
7.3.6 EUSA Pharma Competitive Strengths & Weaknesses
7.4 ANI Pharmaceuticals
7.4.1 ANI Pharmaceuticals Details
7.4.2 ANI Pharmaceuticals Major Business
7.4.3 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
7.4.4 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 ANI Pharmaceuticals Recent Developments/Updates
7.4.6 ANI Pharmaceuticals Competitive Strengths & Weaknesses
7.5 Baxter Healthcare
7.5.1 Baxter Healthcare Details
7.5.2 Baxter Healthcare Major Business
7.5.3 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product and Services
7.5.4 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Baxter Healthcare Recent Developments/Updates
7.5.6 Baxter Healthcare Competitive Strengths & Weaknesses
7.6 Ingenus Pharmaceuticals
7.6.1 Ingenus Pharmaceuticals Details
7.6.2 Ingenus Pharmaceuticals Major Business
7.6.3 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
7.6.4 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
7.6.6 Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
7.7 Pfizer
7.7.1 Pfizer Details
7.7.2 Pfizer Major Business
7.7.3 Pfizer Immunotherapy Drugs for Neuroblastoma Product and Services
7.7.4 Pfizer Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Pfizer Recent Developments/Updates
7.7.6 Pfizer Competitive Strengths & Weaknesses
7.8 Hikma Pharmaceuticals
7.8.1 Hikma Pharmaceuticals Details
7.8.2 Hikma Pharmaceuticals Major Business
7.8.3 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
7.8.4 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Hikma Pharmaceuticals Recent Developments/Updates
7.8.6 Hikma Pharmaceuticals Competitive Strengths & Weaknesses
7.9 Teva Pharmaceuticals
7.9.1 Teva Pharmaceuticals Details
7.9.2 Teva Pharmaceuticals Major Business
7.9.3 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
7.9.4 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Teva Pharmaceuticals Recent Developments/Updates
7.9.6 Teva Pharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Immunotherapy Drugs for Neuroblastoma Industry Chain
8.2 Immunotherapy Drugs for Neuroblastoma Upstream Analysis
8.2.1 Immunotherapy Drugs for Neuroblastoma Core Raw Materials
8.2.2 Main Manufacturers of Immunotherapy Drugs for Neuroblastoma Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Immunotherapy Drugs for Neuroblastoma Production Mode
8.6 Immunotherapy Drugs for Neuroblastoma Procurement Model
8.7 Immunotherapy Drugs for Neuroblastoma Industry Sales Model and Sales Channels
8.7.1 Immunotherapy Drugs for Neuroblastoma Sales Model
8.7.2 Immunotherapy Drugs for Neuroblastoma Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Immunotherapy Drugs for Neuroblastoma Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Immunotherapy Drugs for Neuroblastoma Production Value by Region (2018-2023) & (USD Million)
Table 3. World Immunotherapy Drugs for Neuroblastoma Production Value by Region (2024-2029) & (USD Million)
Table 4. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Region (2018-2023)
Table 5. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Region (2024-2029)
Table 6. World Immunotherapy Drugs for Neuroblastoma Production by Region (2018-2023) & (K Units)
Table 7. World Immunotherapy Drugs for Neuroblastoma Production by Region (2024-2029) & (K Units)
Table 8. World Immunotherapy Drugs for Neuroblastoma Production Market Share by Region (2018-2023)
Table 9. World Immunotherapy Drugs for Neuroblastoma Production Market Share by Region (2024-2029)
Table 10. World Immunotherapy Drugs for Neuroblastoma Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Immunotherapy Drugs for Neuroblastoma Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Immunotherapy Drugs for Neuroblastoma Major Market Trends
Table 13. World Immunotherapy Drugs for Neuroblastoma Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Immunotherapy Drugs for Neuroblastoma Consumption by Region (2018-2023) & (K Units)
Table 15. World Immunotherapy Drugs for Neuroblastoma Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Immunotherapy Drugs for Neuroblastoma Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Immunotherapy Drugs for Neuroblastoma Producers in 2022
Table 18. World Immunotherapy Drugs for Neuroblastoma Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Immunotherapy Drugs for Neuroblastoma Producers in 2022
Table 20. World Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Immunotherapy Drugs for Neuroblastoma Company Evaluation Quadrant
Table 22. World Immunotherapy Drugs for Neuroblastoma Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Immunotherapy Drugs for Neuroblastoma Production Site of Key Manufacturer
Table 24. Immunotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
Table 25. Immunotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
Table 26. Immunotherapy Drugs for Neuroblastoma Competitive Factors
Table 27. Immunotherapy Drugs for Neuroblastoma New Entrant and Capacity Expansion Plans
Table 28. Immunotherapy Drugs for Neuroblastoma Mergers & Acquisitions Activity
Table 29. United States VS China Immunotherapy Drugs for Neuroblastoma Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Immunotherapy Drugs for Neuroblastoma Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Immunotherapy Drugs for Neuroblastoma Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Immunotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Market Share (2018-2023)
Table 37. China Based Immunotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Market Share (2018-2023)
Table 42. Rest of World Based Immunotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Market Share (2018-2023)
Table 47. World Immunotherapy Drugs for Neuroblastoma Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Immunotherapy Drugs for Neuroblastoma Production by Type (2018-2023) & (K Units)
Table 49. World Immunotherapy Drugs for Neuroblastoma Production by Type (2024-2029) & (K Units)
Table 50. World Immunotherapy Drugs for Neuroblastoma Production Value by Type (2018-2023) & (USD Million)
Table 51. World Immunotherapy Drugs for Neuroblastoma Production Value by Type (2024-2029) & (USD Million)
Table 52. World Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Immunotherapy Drugs for Neuroblastoma Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Immunotherapy Drugs for Neuroblastoma Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Immunotherapy Drugs for Neuroblastoma Production by Application (2018-2023) & (K Units)
Table 56. World Immunotherapy Drugs for Neuroblastoma Production by Application (2024-2029) & (K Units)
Table 57. World Immunotherapy Drugs for Neuroblastoma Production Value by Application (2018-2023) & (USD Million)
Table 58. World Immunotherapy Drugs for Neuroblastoma Production Value by Application (2024-2029) & (USD Million)
Table 59. World Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Immunotherapy Drugs for Neuroblastoma Average Price by Application (2024-2029) & (US$/Unit)
Table 61. United Therapeutics Basic Information, Manufacturing Base and Competitors
Table 62. United Therapeutics Major Business
Table 63. United Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
Table 64. United Therapeutics Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. United Therapeutics Recent Developments/Updates
Table 66. United Therapeutics Competitive Strengths & Weaknesses
Table 67. Y-mAbs Therapeutics Basic Information, Manufacturing Base and Competitors
Table 68. Y-mAbs Therapeutics Major Business
Table 69. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
Table 70. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Y-mAbs Therapeutics Recent Developments/Updates
Table 72. Y-mAbs Therapeutics Competitive Strengths & Weaknesses
Table 73. EUSA Pharma Basic Information, Manufacturing Base and Competitors
Table 74. EUSA Pharma Major Business
Table 75. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product and Services
Table 76. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. EUSA Pharma Recent Developments/Updates
Table 78. EUSA Pharma Competitive Strengths & Weaknesses
Table 79. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 80. ANI Pharmaceuticals Major Business
Table 81. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 82. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. ANI Pharmaceuticals Recent Developments/Updates
Table 84. ANI Pharmaceuticals Competitive Strengths & Weaknesses
Table 85. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
Table 86. Baxter Healthcare Major Business
Table 87. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product and Services
Table 88. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Baxter Healthcare Recent Developments/Updates
Table 90. Baxter Healthcare Competitive Strengths & Weaknesses
Table 91. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 92. Ingenus Pharmaceuticals Major Business
Table 93. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 94. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Ingenus Pharmaceuticals Recent Developments/Updates
Table 96. Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
Table 97. Pfizer Basic Information, Manufacturing Base and Competitors
Table 98. Pfizer Major Business
Table 99. Pfizer Immunotherapy Drugs for Neuroblastoma Product and Services
Table 100. Pfizer Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Pfizer Recent Developments/Updates
Table 102. Pfizer Competitive Strengths & Weaknesses
Table 103. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 104. Hikma Pharmaceuticals Major Business
Table 105. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 106. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Hikma Pharmaceuticals Recent Developments/Updates
Table 108. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 109. Teva Pharmaceuticals Major Business
Table 110. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 111. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 112. Global Key Players of Immunotherapy Drugs for Neuroblastoma Upstream (Raw Materials)
Table 113. Immunotherapy Drugs for Neuroblastoma Typical Customers
Table 114. Immunotherapy Drugs for Neuroblastoma Typical Distributors
Table 1. World Immunotherapy Drugs for Neuroblastoma Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Immunotherapy Drugs for Neuroblastoma Production Value by Region (2018-2023) & (USD Million)
Table 3. World Immunotherapy Drugs for Neuroblastoma Production Value by Region (2024-2029) & (USD Million)
Table 4. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Region (2018-2023)
Table 5. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Region (2024-2029)
Table 6. World Immunotherapy Drugs for Neuroblastoma Production by Region (2018-2023) & (K Units)
Table 7. World Immunotherapy Drugs for Neuroblastoma Production by Region (2024-2029) & (K Units)
Table 8. World Immunotherapy Drugs for Neuroblastoma Production Market Share by Region (2018-2023)
Table 9. World Immunotherapy Drugs for Neuroblastoma Production Market Share by Region (2024-2029)
Table 10. World Immunotherapy Drugs for Neuroblastoma Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Immunotherapy Drugs for Neuroblastoma Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Immunotherapy Drugs for Neuroblastoma Major Market Trends
Table 13. World Immunotherapy Drugs for Neuroblastoma Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Immunotherapy Drugs for Neuroblastoma Consumption by Region (2018-2023) & (K Units)
Table 15. World Immunotherapy Drugs for Neuroblastoma Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Immunotherapy Drugs for Neuroblastoma Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Immunotherapy Drugs for Neuroblastoma Producers in 2022
Table 18. World Immunotherapy Drugs for Neuroblastoma Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Immunotherapy Drugs for Neuroblastoma Producers in 2022
Table 20. World Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Immunotherapy Drugs for Neuroblastoma Company Evaluation Quadrant
Table 22. World Immunotherapy Drugs for Neuroblastoma Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Immunotherapy Drugs for Neuroblastoma Production Site of Key Manufacturer
Table 24. Immunotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
Table 25. Immunotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
Table 26. Immunotherapy Drugs for Neuroblastoma Competitive Factors
Table 27. Immunotherapy Drugs for Neuroblastoma New Entrant and Capacity Expansion Plans
Table 28. Immunotherapy Drugs for Neuroblastoma Mergers & Acquisitions Activity
Table 29. United States VS China Immunotherapy Drugs for Neuroblastoma Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Immunotherapy Drugs for Neuroblastoma Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Immunotherapy Drugs for Neuroblastoma Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Immunotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Market Share (2018-2023)
Table 37. China Based Immunotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Market Share (2018-2023)
Table 42. Rest of World Based Immunotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Market Share (2018-2023)
Table 47. World Immunotherapy Drugs for Neuroblastoma Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Immunotherapy Drugs for Neuroblastoma Production by Type (2018-2023) & (K Units)
Table 49. World Immunotherapy Drugs for Neuroblastoma Production by Type (2024-2029) & (K Units)
Table 50. World Immunotherapy Drugs for Neuroblastoma Production Value by Type (2018-2023) & (USD Million)
Table 51. World Immunotherapy Drugs for Neuroblastoma Production Value by Type (2024-2029) & (USD Million)
Table 52. World Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Immunotherapy Drugs for Neuroblastoma Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Immunotherapy Drugs for Neuroblastoma Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Immunotherapy Drugs for Neuroblastoma Production by Application (2018-2023) & (K Units)
Table 56. World Immunotherapy Drugs for Neuroblastoma Production by Application (2024-2029) & (K Units)
Table 57. World Immunotherapy Drugs for Neuroblastoma Production Value by Application (2018-2023) & (USD Million)
Table 58. World Immunotherapy Drugs for Neuroblastoma Production Value by Application (2024-2029) & (USD Million)
Table 59. World Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Immunotherapy Drugs for Neuroblastoma Average Price by Application (2024-2029) & (US$/Unit)
Table 61. United Therapeutics Basic Information, Manufacturing Base and Competitors
Table 62. United Therapeutics Major Business
Table 63. United Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
Table 64. United Therapeutics Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. United Therapeutics Recent Developments/Updates
Table 66. United Therapeutics Competitive Strengths & Weaknesses
Table 67. Y-mAbs Therapeutics Basic Information, Manufacturing Base and Competitors
Table 68. Y-mAbs Therapeutics Major Business
Table 69. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
Table 70. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Y-mAbs Therapeutics Recent Developments/Updates
Table 72. Y-mAbs Therapeutics Competitive Strengths & Weaknesses
Table 73. EUSA Pharma Basic Information, Manufacturing Base and Competitors
Table 74. EUSA Pharma Major Business
Table 75. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product and Services
Table 76. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. EUSA Pharma Recent Developments/Updates
Table 78. EUSA Pharma Competitive Strengths & Weaknesses
Table 79. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 80. ANI Pharmaceuticals Major Business
Table 81. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 82. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. ANI Pharmaceuticals Recent Developments/Updates
Table 84. ANI Pharmaceuticals Competitive Strengths & Weaknesses
Table 85. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
Table 86. Baxter Healthcare Major Business
Table 87. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product and Services
Table 88. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Baxter Healthcare Recent Developments/Updates
Table 90. Baxter Healthcare Competitive Strengths & Weaknesses
Table 91. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 92. Ingenus Pharmaceuticals Major Business
Table 93. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 94. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Ingenus Pharmaceuticals Recent Developments/Updates
Table 96. Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
Table 97. Pfizer Basic Information, Manufacturing Base and Competitors
Table 98. Pfizer Major Business
Table 99. Pfizer Immunotherapy Drugs for Neuroblastoma Product and Services
Table 100. Pfizer Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Pfizer Recent Developments/Updates
Table 102. Pfizer Competitive Strengths & Weaknesses
Table 103. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 104. Hikma Pharmaceuticals Major Business
Table 105. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 106. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Hikma Pharmaceuticals Recent Developments/Updates
Table 108. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 109. Teva Pharmaceuticals Major Business
Table 110. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 111. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 112. Global Key Players of Immunotherapy Drugs for Neuroblastoma Upstream (Raw Materials)
Table 113. Immunotherapy Drugs for Neuroblastoma Typical Customers
Table 114. Immunotherapy Drugs for Neuroblastoma Typical Distributors
LIST OF FIGURES
Figure 1. Immunotherapy Drugs for Neuroblastoma Picture
Figure 2. World Immunotherapy Drugs for Neuroblastoma Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Immunotherapy Drugs for Neuroblastoma Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Immunotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 5. World Immunotherapy Drugs for Neuroblastoma Average Price (2018-2029) & (US$/Unit)
Figure 6. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Region (2018-2029)
Figure 7. World Immunotherapy Drugs for Neuroblastoma Production Market Share by Region (2018-2029)
Figure 8. North America Immunotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 9. Europe Immunotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 10. China Immunotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 11. Japan Immunotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 12. Immunotherapy Drugs for Neuroblastoma Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 15. World Immunotherapy Drugs for Neuroblastoma Consumption Market Share by Region (2018-2029)
Figure 16. United States Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 17. China Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 18. Europe Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 19. Japan Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 20. South Korea Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 22. India Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Immunotherapy Drugs for Neuroblastoma by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Immunotherapy Drugs for Neuroblastoma Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Immunotherapy Drugs for Neuroblastoma Markets in 2022
Figure 26. United States VS China: Immunotherapy Drugs for Neuroblastoma Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Immunotherapy Drugs for Neuroblastoma Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Immunotherapy Drugs for Neuroblastoma Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Market Share 2022
Figure 30. China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Market Share 2022
Figure 32. World Immunotherapy Drugs for Neuroblastoma Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Type in 2022
Figure 34. Dinutuximab
Figure 35. Naxitamab
Figure 36. Other
Figure 37. World Immunotherapy Drugs for Neuroblastoma Production Market Share by Type (2018-2029)
Figure 38. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Type (2018-2029)
Figure 39. World Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029) & (US$/Unit)
Figure 40. World Immunotherapy Drugs for Neuroblastoma Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 41. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Application in 2022
Figure 42. Hospital
Figure 43. Clinic
Figure 44. Other
Figure 45. World Immunotherapy Drugs for Neuroblastoma Production Market Share by Application (2018-2029)
Figure 46. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Application (2018-2029)
Figure 47. World Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029) & (US$/Unit)
Figure 48. Immunotherapy Drugs for Neuroblastoma Industry Chain
Figure 49. Immunotherapy Drugs for Neuroblastoma Procurement Model
Figure 50. Immunotherapy Drugs for Neuroblastoma Sales Model
Figure 51. Immunotherapy Drugs for Neuroblastoma Sales Channels, Direct Sales, and Distribution
Figure 52. Methodology
Figure 53. Research Process and Data Source
Figure 1. Immunotherapy Drugs for Neuroblastoma Picture
Figure 2. World Immunotherapy Drugs for Neuroblastoma Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Immunotherapy Drugs for Neuroblastoma Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Immunotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 5. World Immunotherapy Drugs for Neuroblastoma Average Price (2018-2029) & (US$/Unit)
Figure 6. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Region (2018-2029)
Figure 7. World Immunotherapy Drugs for Neuroblastoma Production Market Share by Region (2018-2029)
Figure 8. North America Immunotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 9. Europe Immunotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 10. China Immunotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 11. Japan Immunotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 12. Immunotherapy Drugs for Neuroblastoma Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 15. World Immunotherapy Drugs for Neuroblastoma Consumption Market Share by Region (2018-2029)
Figure 16. United States Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 17. China Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 18. Europe Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 19. Japan Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 20. South Korea Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 22. India Immunotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Immunotherapy Drugs for Neuroblastoma by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Immunotherapy Drugs for Neuroblastoma Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Immunotherapy Drugs for Neuroblastoma Markets in 2022
Figure 26. United States VS China: Immunotherapy Drugs for Neuroblastoma Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Immunotherapy Drugs for Neuroblastoma Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Immunotherapy Drugs for Neuroblastoma Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Market Share 2022
Figure 30. China Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Immunotherapy Drugs for Neuroblastoma Production Market Share 2022
Figure 32. World Immunotherapy Drugs for Neuroblastoma Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Type in 2022
Figure 34. Dinutuximab
Figure 35. Naxitamab
Figure 36. Other
Figure 37. World Immunotherapy Drugs for Neuroblastoma Production Market Share by Type (2018-2029)
Figure 38. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Type (2018-2029)
Figure 39. World Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029) & (US$/Unit)
Figure 40. World Immunotherapy Drugs for Neuroblastoma Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 41. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Application in 2022
Figure 42. Hospital
Figure 43. Clinic
Figure 44. Other
Figure 45. World Immunotherapy Drugs for Neuroblastoma Production Market Share by Application (2018-2029)
Figure 46. World Immunotherapy Drugs for Neuroblastoma Production Value Market Share by Application (2018-2029)
Figure 47. World Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029) & (US$/Unit)
Figure 48. Immunotherapy Drugs for Neuroblastoma Industry Chain
Figure 49. Immunotherapy Drugs for Neuroblastoma Procurement Model
Figure 50. Immunotherapy Drugs for Neuroblastoma Sales Model
Figure 51. Immunotherapy Drugs for Neuroblastoma Sales Channels, Direct Sales, and Distribution
Figure 52. Methodology
Figure 53. Research Process and Data Source
